

PROMOTION RECOMMENDATION  
THE UNIVERSITY OF MICHIGAN  
MEDICAL SCHOOL  
DEPARTMENT OF UROLOGY

Todd M. Morgan, M.D., assistant professor of urology, Department of Urology, Medical School, is recommended for promotion to associate professor of urology, with tenure, Department of Urology, Medical School.

Academic Degrees:

M.D.	2003	Harvard Medical School
B.A.	1999	Harvard University

Professional Record:

2012-present	Assistant Professor of Urology, University of Michigan
2011-2012	Assistant Professor of Urologic Surgery, Vanderbilt University
2009-2011	Clinical Instructor, Department of Urologic Surgery, Vanderbilt University

Summary of Evaluation:

Teaching: Dr. Morgan has dedicated approximately 10% of his effort to teaching and educational activities in the clinic, on hospital rounds, and in the operating room. He teaches in the laboratory to undergraduate students and lectures annually in a M2 renal sequence on prostate pathophysiology. He has mentored five M3 and M4 students during their urology rotations on research projects. A critical component of Dr. Morgan's teaching is the supervision and training of residents in the Cancer Center outpatient clinic, working with them to perform open, laparoscopic, and robotic oncologic surgeries as well as training on emergency department consults, rounds, journal clubs, and research projects in which he is a primary mentor for three residents. Dr. Morgan has mentored four urologic oncology fellows on the management of complex patients with genitourinary malignancies. He mentors Ph.D. and post-doctoral fellows and gives talks to kidney, bladder, and prostate cancer support group meetings throughout the state. Other important teaching contributions include course design for a Prostate MR/US Fusion Guided Biopsy course held at the University of Michigan and courses led at national and international meetings. Dr. Morgan developed a National Testis Cancer Curriculum for Urologic Oncology Fellows as president elect of the Young Urologic Oncology Committee of the Society of Urology Oncology. He has run the monthly morbidity and mortality teaching conference for the Department of Urology for the past three years. Dr. Morgan is the co-founder and co-manager of UrologyMatch.com which is a widely used educational website for medical students and urology residents. In 2014, Dr. Morgan received the Silver Cystoscope Award for Excellence in Urology Resident Education.

Research: Dr. Morgan's primary research interest centers on clinically meaningful biomarkers in genitourinary malignancies. His research laboratory focuses on biomarkers associated with treatment efficacy, aiming to facilitate precision-based therapies, and to help understand key mechanisms of disease resistance. He has been developing a liquid biopsy program for prostate cancer. Dr. Morgan has produced 56 peer-reviewed publications, seven non-peer-reviewed publications, five book chapters, one book, and 96 abstracts. He serves as the principal investigator for eight grants totaling \$1.7M and is a co-investigator on a U54 and P01 grant. He has an R01 and a SubK-NH-DHHS-US grant submitted. Dr. Morgan received in 2014 the Prostate Cancer Foundation Young Investigator Award, and in 2015 the National Comprehensive Cancer Network Young Investigator Award and the Society for Basic Urologic Research Young Investigator Award. He serves on the editorial boards for three journals and is a reviewer for 24 scientific journals. Dr. Morgan has three patents submitted, one as inventor and two as co-inventor.

Recent and Significant Publications:

Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE: Imaging the clear cell renal cell carcinoma proteome. *J Urol* 189:1097-1103, 2013.

Davies JD, Simons CM, Ruhotina N, Barocas DA, Clark PE, Morgan TM: Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. *Urology* 81:358-363, 2013.

Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW: A risk-adjusted definition of biochemical recurrence after radical prostatectomy. *Prostate Cancer Prostatic Dis* 17:174-179, 2014.

Zaslavsky AB, Gloeckner-Kalaousek A, Adams M, Nagireddy P, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS: Platelet-synthesized testosterone in men with prostate cancer induces androgen receptor signaling. *Neoplasia* 17:490-496, 2015.

Pham KN, Porter CR, Odem-Davis K, Wolff EM, Jeldres C, Wei JT, Morgan TM: Transperineal template guided prostate biopsy selects candidates for active surveillance: How many cores are enough? *J Urol* 194:674-679, 2015.

Service: Dr. Morgan is a member of eight professional societies including the American Urological Association, American Association of Cancer Research, Society of Urologic Oncology, and Association on Clinical and Translational Science. He served as a co-chair of the European Association of Urology Social Media Ethics Guideline Committee in 2014. He currently serves as a panel member of the National Comprehensive Cancer Network Prostate Cancer Early Detection Guidelines, as president elect of the Young Urology Oncologists Board of the Society of Urology Oncology as well as a member of the Society of Urologic Oncology Finance Committee. Institutionally, he serves on four committees and chairs the Department of Urology Peer Review Committee. He has volunteered his services at the IVUMed at Salt Lake City, Utah as well as Ulaanbaatar, Mongolia. He is co-founder and developer of drawMD, a suite of iPad applications for physician-patient counseling.

Dr. Morgan is a urological oncologist with a clinical focus on treating patients with genitourinary tumors in the Comprehensive Cancer Center. He performs both open and robotic surgeries of the prostate, bladder, kidney, testis, and retroperitoneal or inguinal lymph nodes. He has developed a strong referral base. One internal reviewer commented, "He is well-liked by patients and staff and I have had the pleasure of sharing the care of a number of patients with him over the last three years. He consistently delivers care of the highest quality and I would have no hesitation to recommend him to my own family and friends."

#### External Reviewers:

Reviewer A: "In brief, Dr. Morgan comes from an impeccable educational background, has utilized opportunities and resources available to him to build upon this educational background, has taken leadership roles in developing research programs and clinical programs, and is well on the way to becoming a leader in urologic oncology at both the laboratory research and clinical levels....Dr. Morgan's scholarship has already impacted his areas of interest and resulted in advances in which we can further understand the biologic aspects in the pathogenesis of prostate cancer and kidney cancer. I personally would rank Dr. Morgan's scholarly and professional niche at the highest level in comparison with his peers. I have no doubt that this individual would likely achieve equivalent rank for the position for which is being considered not only at my institution, but at leading institutions nationally and internationally."

Reviewer B: "With 54 publications to his credit in leading urologic journals, his work clearly has an impact in patient care. He has been successful at getting funding as a co-investigator on 2 NIH grants and a [junior] investigator grant from the NCCN. He is currently focused on identification of key pathways that predict response to treatment in prostate and renal carcinoma. These are two diseases in which the past decade has seen some remarkable advances in the care of patients with advanced disease. This has raised new problems, focused on when to treat and who to treat. Work, such as Dr. Morgan's, will be critical in guiding treatment decisions."

Reviewer C: "Dr. Morgan has established himself as a thought leader in urologic oncology. I have noticed over the years that he is sought out by colleagues at our regional and national meetings for his opinion on patient management as well as on academic and research matters. I would consider him an expert in the area of prostate, kidney, and bladder cancer prognostication and molecular markers. Dr. Morgan is engaged in interdisciplinary research with colleagues in basic science, pathology, and other disciplines. This is especially notable for a practicing clinical urologist who is busy and stands out as a very positive factor when compared with his peers across the country."

Reviewer D: "The strength of his CV clearly is related to the activity in current grants and study in an area that is key to learning more about managing urinary malignancies specifically determining patient treatment needs and providing stratification of the risk of Urologic malignancies....The fact that he is a journal reviewer on editorial boards of multiple publications, further attests to the fact that his opinion has been sought after on a national level in his area of expertise. Likewise, his national and international participation in invited

presentations suggest strongly that he already has a well-known presence in his area of expertise.”

Reviewer E: “Dr. Morgan's national reputation has grown since his appointment, and I believe he is well known and extremely well regarded by the majority of his peers in the field of urologic oncology....Most impressive has been his grant funding record. Todd has amassed considerable funding, both as a co-investigator and as a primary investigator, including one R01 equivalent. This is a testament to both his individual motivation as a physician scientist and his institutional environment. He appears to have very effectively collaborated with the research community at Michigan to care out an area of independent study.”

Summary of Recommendation:

Dr. Morgan is an excellent clinician, educator, citizen, and translational researcher in the Urology Department. He is a rising star in the field of urologic oncology. I wholeheartedly recommend Todd M. Morgan, M.D. for promotion to associate professor of urology, with tenure, Department of Urology, Medical School.



---

Marschall S. Runge, M.D., Ph.D.  
Executive Vice President for Medical Affairs  
Dean, Medical School

May 2016